Clinical Trials – Not Recruiting
Mesothelioma clinical trials only accept a certain number of patients. Once that number is reached, the study halts enrollment. Doctors continue treating and monitoring enrolled patients until the study ends. Ongoing clinical trials provide important information about new mesothelioma treatments.
Learn About Mesothelioma Clinical Trials in Our Free Guide
Ongoing Mesothelioma Clinical Trials
Clinical trials are designed to test new treatments as efficiently as possible. Part of this design means only a certain number of patients can be accepted into each study. Once a mesothelioma study reaches this enrollment target, no additional mesothelioma patients are accepted. The study is still considered to be ongoing, as doctors continue treating and monitoring existing study patients.
Some clinical trials release preliminary study results during this time period. For instance, the CheckMate 743 clinical trial did this in 2020. CheckMate 743 investigated the use of two immunotherapy drugs compared to standard chemotherapy treatment.
The immunotherapy drug combination (nivolumab and ipilimumab) performed better than standard chemotherapy. Patients treated with the immunotherapy drugs lived about four months longer than those receiving chemotherapy.
After reviewing the study results, the U.S. Food and Drug Administration (FDA) approved the immunotherapy drugs. Specifically, nivolumab and ipilimumab were approved for the treatment of inoperable pleural mesothelioma.
If you or a loved one are considering enrolling in a clinical trial, you can find open studies on our Clinical Trials – Recruiting page.
Ongoing Mesothelioma Clinical Trials Not Recruiting Patients
Provided below is a list of mesothelioma trials that are no longer accepting new patients.
Note: The information below is provided by ClinicalTrials.gov.
Conditions: Mesothelioma
Last Updated: 2/13/2026
Status: Active, not recruiting
Conditions: Mesothelioma
Last Updated: 2/3/2026
Status: Active, not recruiting
A Study of SGN-MesoC2 in Advanced Solid Tumors
Conditions: Mesothelioma
Last Updated: 1/12/2026
Status: Active, not recruiting
Conditions: Mesothelioma
Last Updated: 1/6/2026
Status: Active, not recruiting
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
Conditions: Mesothelioma
Last Updated: 1/5/2026
Status: Active, not recruiting
Conditions: Mesothelioma
Last Updated: 12/26/2025
Status: Active, not recruiting
Conditions: Mesothelioma
Last Updated: 11/21/2025
Status: Active, not recruiting
Conditions: Mesothelioma
Last Updated: 11/14/2025
Status: Active, not recruiting
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
Conditions: Mesothelioma
Last Updated: 11/14/2025
Status: Active, not recruiting
Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: 11/13/2025
Status: Active, not recruiting
Conditions: Mesothelioma
Last Updated: 11/10/2025
Status: Active, not recruiting
Conditions: Mesothelioma
Last Updated: 10/29/2025
Status: Active, not recruiting
Stereotactic Body Radiation Therapy With Immunotherapy for the Treatment of Mesothelioma
Conditions: Mesothelioma
Last Updated: 10/22/2025
Status: Active, not recruiting
Conditions: Mesothelioma
Last Updated: 10/16/2025
Status: Active, not recruiting
Conditions: Mesothelioma
Last Updated: 10/8/2025
Status: Active, not recruiting
A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors
Conditions: Mesothelioma
Last Updated: 9/19/2025
Status: Active, not recruiting
A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
Conditions: Mesothelioma
Last Updated: 9/12/2025
Status: Active, not recruiting
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
Conditions: Mesothelioma
Last Updated: 9/9/2025
Status: Active, not recruiting
Conditions: Mesothelioma
Last Updated: 9/9/2025
Status: Active, not recruiting
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
Conditions: Mesothelioma
Last Updated: 8/27/2025
Status: Active, not recruiting
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
Conditions: Mesothelioma
Last Updated: 8/27/2025
Status: Active, not recruiting
Conditions: Mesothelioma
Last Updated: 8/15/2025
Status: Active, not recruiting
Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma
Conditions: Mesothelioma
Last Updated: 7/25/2025
Status: Active, not recruiting
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: 6/26/2025
Status: Active, not recruiting
Pembrolizumab in Treating Patients With Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: 6/11/2025
Status: Active, not recruiting
Conditions: Mesothelioma
Last Updated: 5/20/2025
Status: Active, not recruiting
Conditions: Mesothelioma
Last Updated: 5/11/2025
Status: Active, not recruiting
Conditions: Mesothelioma
Last Updated: 10/10/2024
Status: Active, not recruiting
Conditions: Mesothelioma
Last Updated: 10/2/2024
Status: Active, not recruiting
Conditions: Mesothelioma
Last Updated: 4/1/2024
Status: Active, not recruiting
Sources
American Cancer Society. Deciding Whether to Be Part of a Clinical Trial. Updated August 2020.
American Cancer Society. What’s New in Malignant Mesothelioma Research? Updated May 2019.
Baas P, Scherpereel A, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. January 2021;397(10272):375-386. doi: 10.1016/S0140-6736(20)32714-8
Ghirardelli P, Franceschini D, et al. Salvage radiotherapy for oligo-progressive malignant pleural mesothelioma. Lung Cancer. February 2021;152:1-6. doi: 10.1016/j.lungcan.2020.11.022
Kindler HL, Ismaila N, et al. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology. May 2018;36(13):1343-1373. doi: 10.1200/JCO.2017.76.6394
Lau B, Boyer M, et al. Clinical Trials Eligibility of Patients With Malignant Pleural Mesothelioma: Use of Novel Therapies and Outcomes. Clinical Lung Cancer. July 2020;21(4):378-383.e1. doi: 10.1016/j.cllc.2020.01.007
Moffitt Cancer Center. Mesothelioma Clinical Trials.
National Cancer Institute. Paying for Clinical Trials. Updated February 2020.
National Cancer Institute. What Are Clinical Trials? Updated November 2021.
National Institute on Aging. Clinical Trials: Benefits, Risks, and Safety. Updated May 2017.
National Institutes of Health. NIH Clinical Research Trials and You: The Basics. Updated October 2017.
Rintoul RC, Ritchie AJ, et al. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet. September 2014;384(9948):1118-27. doi: 10.1016/S0140-6736(14)60418-9
Warnock C, Lord K, et al. Patient experiences of participation in a radical thoracic surgical trial: findings from the Mesothelioma and Radical Surgery Trial 2 (MARS 2). Trials. October 2019;20(1):598. doi: 10.1186/s13063-019-3692-x
Wright K. FDA Approves Nivolumab Plus Ipilimumab for Previously Untreated Unresectable Malignant Pleural Mesothelioma. Oncology (Williston Park). November 2020;34(11):502-503.
Yap TA, Nakagawa K, et al. Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. The Lancet Respiratory Medicine. June 2021;9(6):613-621. doi: 10.1016/S2213-2600(20)30515-4
Free Mesothelioma Treatment Guide
Katy Moncivais, Ph.D., has more than 15 years of experience as a medical communicator. As the Medical Editor at Mesothelioma.com, she ensures our pages and posts present accurate, helpful information.
Annette Charlevois is a Patient Support Coordinator for Mesothelioma.com. For more than 20 years, she has helped thousands of mesothelioma patients and their families get the assistance they need.
